# Subependymoma — Adversarial Verification Verdict

1. DOSE LEAK: none. Grepped for mg/Gy/AUC/% and all numeric tokens in the file — the only digit
   in the entire document is "12" in the source citation ("12th ed."). No dose, mg/m2, AUC, or
   numbered schedule anywhere.

2. UNGROUNDED CLAIMS: none found. Checked devita.txt (lines ~241280-241398, Chapter 64) — the
   DeVita subependymoma passage reads: "Subependymomas represent a distinct benign entity that
   includes an admixture of fibrillary subependymal astrocytes. They are most commonly found in
   the floor or walls of the fourth ventricle in older men. Most are asymptomatic and slow
   growing. Treatment is rarely needed except in cases of hydrocephalus or demonstrated growth.
   Typically, they are incidentally identified at autopsy." The sidecar's Overview paraphrases
   this closely and accurately, with no added drugs, trial names, or statistics attributed to
   DeVita for this entity. Every non-DeVita claim (surgical resection as definitive treatment,
   GTS being curative, CSF diversion for hydrocephalus, surveillance MRI, mixed
   subependymoma-ependymoma tumors deferring to ependymoma RT management) is explicitly and
   correctly labelled "general oncology standard, not from DeVita's section on this disease." The
   one adjacent-entity claim (postoperative RT as an adjunct for ependymoma after resection,
   especially with STR/higher grade) is consistent with DeVita's Ependymoma/Radiation Therapy
   subsection in the same chapter and is correctly attributed to that separate section, not
   fabricated as subependymoma-specific data. No uncontroversial-but-unlabelled claims found; no
   invented statistics (recurrence rate, survival) appear anywhere, consistent with the draft
   agent's stated omission.

3. CITATION: present — "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice
   of Oncology, 12th ed." Name only, no page numbers. Correct.

4. VERDICT: CLEAN (ready for R1).
